Choose your country or region

Disclaimer

For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.

Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.

This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.

MADIT-CRT Long Term Follow-up

Status: Ongoing

The Boston Scientific sponsored MADIT CRT Long-Term Follow-Up results were presented March 30th, 2014 during the Late Breaking session at the American College of Cardiology meeting in Washington DC, and published online in the New England Journal of Medicine.

MADIT-CRT enrolled 1820 patients with an ejection fraction ≤ 30%, QRS ≥ 130 msec, and NYHA I/II. Patients were randomized to Boston Scientific CRT-D vs. ICD-only and were followed over an average of 2.4 yrs. A subset of 1691 MADIT-CRT patients from the original study cohort were included in the long-term follow-up study and followed through September 30, 2013 for an average follow-up 5.6 years

In the MADIT CRT Long-Term Follow-Up study, patients with left bundle branch block (LBBB) who received a CRT-D demonstrated a significant and sustained survival benefit and had a reduction in first heart failure events compared to patients who received an ICD.

The relative risk of mortality was reduced by 41% in LBBB patients who received CRT-D compared to ICD

This mortality reduction corresponds to a number needed to treat (NNT) of 9; or 1 life saved over 7 years for every 9 patients who receive a CRT-D

Over 80% of patients who received CRT therapy were still alive at 7 years

CRT-D patients had a 62% reduction in the relative risk of a first heart failure event compared to patients who did not receive CRT

Caution: The law restricts this device to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Information not intended for use or distribution in France.